U.K. drugmaker Theramex is in talks with the FDA about supplying estrogen patches in the U.S. as demand for menopause hormone therapy strains supplies, according to a Nov. 16 Bloomberg report.
Theramex, one of the largest producers of menopause hormone therapy in the U.K., has expanded manufacturing capacity in anticipation that the FDA might allow it to sell its patches in the U.S., CEO Robert Stewart told Bloomberg. The company sells an estrogen patch called Evorel in the U.K. but does not have an approved product in the U.S.
“We’ve been in dialogue with the FDA,” Mr. Stewart said, adding that the agency has the information it would need to authorize a special import and that Theramex could respond immediately if it did. Monthly shipments would be “substantial,” he said. Theramex plans to seek FDA approval for its patches in the first half of 2027. An FDA spokesperson declined to discuss details or timing with Bloomberg.
The FDA has said estradiol patches do not meet its criteria for a national shortage, even as the American Society of Health-System Pharmacists has listed certain patch products in shortage since January. The agency said in September that it is working with all six manufacturers of FDA-approved estradiol patches and that supply has nearly doubled over the past year. Demand rose after the FDA’s November 2025 request to remove boxed warnings on breast cancer, cardiovascular disease and probable dementia from hormone therapy labels. The agency approved revised labeling for three additional patch products last month.
The split between the FDA’s and ASHP’s assessments has persisted for months, and patient advocacy groups have pressed the agency to declare a shortage. Pharmacies in some markets have reported shortages, while the FDA disputed broader shortage concerns in May, when ASHP listed 14 brands or dosages of estrogen patches on its shortage list.